

SMALL MOLECULE MEDICINAL CHEMISTRY

Strategies and Technologies

Edited by

WERNGARD CZECHTIZKY

PETER HAMLEY

WILEY

CONTENTS

LIST OF CONTRIBUTORS	xiii
Introduction	1
<i>Werngard Czechtizky and Peter Hamley</i>	
PART I EXPLORING BIOLOGICAL SPACE: ACCESS TO NEW COLLECTIONS	11
1 Elements for the Development of Strategies for Compound Library Enhancement	13
<i>Edgar Jacoby</i>	
1.1 Introduction, 13	
1.2 Chemical Space for Drug Discovery, 14	
1.3 Molecular Properties for Drug Discovery, 17	
1.4 Major Compound Classes, 21	
1.5 Chemical Design Approaches to Expand Bioactive Chemical Space, 25	
1.6 Conclusion, 28	
Acknowledgments, 29	
References, 29	
2 The European Lead Factory	37
<i>Christopher Kallus, Jörg Hüser, Philip S. Jones, and Adam Nelson</i>	
2.1 Introduction, 37	
2.1.1 Background, 37	
2.1.2 The European Lead Factory, 38	

2.2	Building the Joint European Compound Library, 43	
2.2.1	Definition of Criteria and an Approach for the Review and Selection of Library Proposals, 46	
2.2.2	Collation, Review, and Selection of an Initial Wave of Library Proposals, 47	
2.2.3	A Web-Based Tool to Support the Collation, Review, and Selection of Proposals, 49	
2.2.4	Synthetic Validation of Library Proposals and Library Production, 49	
2.3	Qualified Hit Generation, 54	
2.3.1	Capabilities of the ESC, 54	
2.3.2	Target Selection and Generation of Qualified Hits, 56	
2.3.3	Exploitation of Qualified Hit List, 58	
2.4	Future Perspectives, 58	
	Acknowledgments, 59	
	References, 59	
3	Access to Compound Collections: New Business Models for Compound Acquisition and Sharing	61
	<i>Peter ten Holte</i>	
3.1	Introduction, 61	
3.1.1	Vertical Disintegration and the Quest for Innovation, 61	
3.1.2	Innovative Chemistry, 63	
3.1.3	Access to Supplementary Compound Collections, 63	
3.2	Risk-Sharing Approaches, 64	
3.2.1	Overview, 64	
3.2.2	Blinded Screening, 65	
3.2.3	Follow-Up of Blinded Screening: Various Models, 65	
3.3	Library Exchange, 69	
3.3.1	Partners with Different Scientific Interests, 70	
3.3.2	Partners with Similar Scientific Interests, 70	
3.3.3	Compound Selection: Use and Potential Risks, 71	
3.4	Sharing Collections for External Screening, 72	
3.4.1	Rationale, 72	
3.4.2	Academic Drug Discovery Consortium (ADDC), 72	
3.4.3	EU-OPENSREEN, 73	
3.4.4	NIH Roadmap, 73	
3.5	Conclusion, 74	
	Acknowledgments, 74	
	References, 75	

PART II EXPLORING BIOLOGICAL SPACE: ACCESS TO NEW CHEMISTRIES

77

4 New Advances in Diversity-Oriented Synthesis

79

Warren R. J. D. Galloway, Jamie E. Stokes, and David R. Spring

- 4.1 Introduction: Small Molecules and Biology, 79
- 4.2 The Need for Structural Diversity in Synthetic Small Molecule Screening Collections, 80

4.3	Diversity-Oriented Synthesis of New Structurally Diverse Compound Collections, 82	
4.3.1	General Principles of Diversity-Oriented Synthesis, 82	
4.3.2	Achieving Structural Diversity: The Importance of Scaffold Diversity, 83	
4.3.3	Synthetic Principles in DOS, 83	
4.3.4	Scaffold Diversity and Molecular Type, 86	
4.3.5	Examples of DOS Campaigns, 86	
4.4	Concluding Remarks, 97	
	References, 98	
5	Solid-Phase Combinatorial Chemistry	103
	<i>Marcel Patek, Martin Smrcina, Eric Wegrzyniak, Victor Nikolaev, and Andres Mariscal</i>	
5.1	Introduction, 103	
5.2	Chapter Outline, 104	
5.3	Combinatorial Chemistry in Retrospect, 104	
5.4	Foundations of Solid-Phase Synthesis of Combinatorial Chemistry, 107	
5.4.1	Ingredients of Solid-Phase Chemistry, 109	
5.4.2	Library Development and Production, 117	
5.4.3	Analytical Chemistry and Solid-Phase Synthesis of Libraries, 129	
5.5	The Outcome of Tucson Combinatorial Chemistry at Sanofi, 132	
5.5.1	Overall Strategy, 132	
5.5.2	Drug Discovery Outcomes, 134	
5.5.3	Key Parameters of Combichem Productivity, 134	
5.6	Conclusions and Outlook, 135	
	References, 136	
6	Recent Advances in Multicomponent Reaction Chemistry: Applications in Small Molecule Drug Discovery	145
	<i>Christopher Hulme, Muhammad Ayaz, Guillermo Martinez-Ariza, Federico Medda, and Arthur Shaw</i>	
6.1	Introduction, 145	
6.2	Classical Multi-Component Reactions (MCRs), 147	
6.3	The Passerini Reaction (Mario Passerini, 1921), 147	
6.4	Ugi Reaction, 147	
6.4.1	The Ugi-deprotect-cyclize (UDC) strategy, 152	
6.4.2	Bi-functional approach (BIFA), 153	
6.4.3	Miscellaneous Post-Ugi Condensations, 154	
6.5	Van Leusen Reaction, 154	
6.6	Petasis Reaction, 155	
6.7	Groebke–Blackburn–Bienaymé (GBB) Reaction, 155	
6.8	Recently Discovered Novel MCRs, 155	
6.8.1	Cyclic Anhydride-Based MCRs, 155	
6.8.2	1-Azadiene-Based MCRs, 156	
6.8.3	Recent IMCRs and Secondary Reactions, 157	
6.8.4	Miscellaneous MCRs, 159	
6.9	Asymmetric MCRs, 159	

- 6.10 Applications of MCRs in Medicinal Chemistry, 160
 - 6.10.1 Kinase Inhibitors, 161
 - 6.10.2 Protease Inhibitors, 163
 - 6.10.3 Ion Channel Inhibitors, 165
 - 6.10.4 Protein-Protein Interaction Inhibitors, 165
 - 6.10.5 Tubulin Polymerization Inhibitors, 166
 - 6.10.6 G-Protein-Coupled Receptors, 168
- 6.11 Summary, 171
- References, 171

PART III SCREENING STRATEGIES **189**

7 Computational Techniques to Support Hit Triage **191**

Douglas B. Kitchen and H el ene Y. Decornez

- 7.1 Lead Finding Process: Overview and Challenges, 191
 - 7.1.1 The Need for Triage, 191
 - 7.1.2 The Lead Generation Process, 191
 - 7.1.3 Hit Triage: From Actives to Hits to Hit Series, 193
 - 7.1.4 Challenges to Successful Lead Finding, 194
 - 7.1.5 Frequent Hitters, 195
 - 7.1.6 Implications of Human Decision-Making, 195
- 7.2 Chemical Structure Analysis of Hit Lists, 196
 - 7.2.1 Similarity-Based Clustering, 197
 - 7.2.2 Scaffold-Based Clustering, 198
 - 7.2.3 Application of Clustering Classification Methods, 201
- 7.3 Rules and Filters, 201
 - 7.3.1 Computational Descriptors for Property Assessment, 202
 - 7.3.2 Lipophilicity and Other Physicochemical Descriptors, 205
 - 7.3.3 Structural and Shape Descriptors, 205
 - 7.3.4 Multiparameter Calculations: MPO and QED, 206
 - 7.3.5 Frequent-Hitter Analysis, 207
 - 7.3.6 Reactive Group Analysis, 209
- 7.4 Triage Systems, 210
- 7.5 Ligand Efficiency Indices, 210
- 7.6 Hit Series Analysis, 211
 - 7.6.1 Latent Hit Series and Singletons, 211
 - 7.6.2 Rapid Hit Exploration and Compound Set Enrichment, 211
 - 7.6.3 SAR Analysis, 212
 - 7.6.4 Data Volume, Integration, Retrieval, and Visualization, 213
- 7.7 Summary, 214
- References, 214

8 Fragment-Based Drug Discovery **221**

Jean-Paul Renaud, Thomas Neumann, and Luc Van Hijfte

- 8.1 Introduction, 221
- 8.2 Fragment Libraries, 223

- 8.3 Biophysical Screening Technologies, 223
 - 8.3.1 Surface Plasmon Resonance (SPR), 224
 - 8.3.2 Nuclear Magnetic Resonance (NMR), 231
 - 8.3.3 X-Ray Crystallography, 234
 - 8.3.4 Noncovalent Mass Spectrometry, 235
 - 8.3.5 Differential Scanning Fluorimetry (DSF), 237
 - 8.3.6 Biophysical Techniques for Fragment Screening against Membrane Proteins, 238
 - 8.3.7 Biophysical Techniques for Fragment Screening against PPIs, 238
- 8.4 Fragment Evolution Strategies, 239
- 8.5 FBDD Case Studies, 240
 - 8.5.1 Aurora Kinase Inhibitors, 240
 - 8.5.2 Tackling PPIs: Fragment-Based Discovery of Bromodomain Inhibitor Leads, 241
- 8.6 The Future, 243
- References, 244

9 Virtual Screening

251

Karl-Heinz Baringhaus and Gerhard Hessler

- 9.1 Introduction, 251
 - 9.1.1 Goals of Virtual Screening, 252
- 9.2 Databases and Database Preparation, 254
- 9.3 Validation of the Virtual Screening Strategy, 256
- 9.4 Ligand-Based Virtual Screening, 258
 - 9.4.1 2D Approaches, 259
 - 9.4.2 3D Ligand-Based Approaches, 261
- 9.5 Structure-Based Virtual Screening, 263
- 9.6 Other Virtual Screening Applications, 266
- 9.7 Conclusion, 268
- References, 269

10 Phenotypic Screening

281

Michelle Palmer

- 10.1 Introduction, 281
- 10.2 History and Past Successes, 282
- 10.3 Impact of Phenotypic Screening, 282
- 10.4 Model Systems for Phenotypic Assays, 285
 - 10.4.1 Cell Lines, 285
 - 10.4.2 Primary and Stem Cells, 285
 - 10.4.3 Cocultures, 286
 - 10.4.4 3D Cell Models, 287
- 10.5 Assays, 287
 - 10.5.1 Assay Technologies, 287
 - 10.5.2 Assay Development Considerations, 290
 - 10.5.3 Example 1: Selective Killing of Breast Cancer Stem Cells, 291
 - 10.5.4 Example 2: CFTR Potentiator Drug, 291

- 10.6 Deorphaning, 292
 - 10.6.1 Affinity-Based Proteomics, 292
 - 10.6.2 Genetic Profiling, 295
 - 10.6.3 Target Profiling, 296
 - 10.6.4 Comodifier Profiling, 296
 - 10.6.5 Target Engagement, 297
 - 10.6.6 Example 3: Elucidating MOA for a Regulator of Polyploidization, 297
- 10.7 Summary, 298
- References, 299

PART IV TECHNOLOGIES FOR MEDICINAL CHEMISTRY OPTIMIZATION

305

11 Advances in the Understanding of Drug Properties in Medicinal Chemistry

307

Peter Hamley and Patrick Jimonet

- 11.1 Introduction, 307
- 11.2 Properties and Origins of Marketed Drugs, 308
 - 11.2.1 The Consistent Properties of Oral Drugs, 308
 - 11.2.2 The Changing Origins of Oral Drugs, 308
- 11.3 Drug Properties and Attrition in Clinical Development, 310
- 11.4 The Rule of Five, 312
 - 11.4.1 The Concept, 312
 - 11.4.2 Druggability, 313
- 11.5 The Concept of Lead-Likeness, 313
 - 11.5.1 The Consequences on Screening and Collections, 314
- 11.6 Influence of Drug Properties on Absorption, Distribution, Metabolism, Excretion, and Toxicity, 314
- 11.7 Building on the Ro5: New Guidelines for Compound Design, 316
 - 11.7.1 Ligand Efficiency, 316
 - 11.7.2 Ligand Lipophilicity Efficiency and Other Indices, 317
 - 11.7.3 Chemical Beauty, 318
- 11.8 Alternatives, Criticisms, and Exceptions, 318
- 11.9 Conclusions, 320
- References, 320

12 Recent Developments in Automated Solution Phase Library Production

323

Thomas C. Maier and Werngard Czechtizky

- 12.1 Introduction, 323
 - 12.1.1 Introduction and Definitions, 323
 - 12.1.2 Library Types, 324
 - 12.1.3 Chemotypes, 326

- 12.2 Library Production, 327
 - 12.2.1 The Library Production Process, 327
 - 12.2.2 Process Optimization, 330
- 12.3 New Technologies in Automated Liquid-Phase Library Synthesis, 334
 - 12.3.1 Provision of Starting Materials: Automated Reagent Dispensaries, 334
 - 12.3.2 Microwave, 335
 - 12.3.3 Library Purification: Automated RP-HPLC and SFC as Orthogonal Methods, 336
- 12.4 Flow Chemistry and Gas-Phase Reactions, 342
 - 12.4.1 Reactive Gases in Flow, 344
- 12.5 Conclusion, 345
- References, 345

13 ADME Profiling: An Introduction for the Medicinal Chemist

353

Katharina Mertsch, Martin Will, Werngard Czechtizky, Niels Griesang, Alexander Marker, and Jacob Olsen

- 13.1 Introduction, 353
- 13.2 Compound Profiling in H2L Optimization, 354
 - 13.2.1 Intestinal Absorption, 354
 - 13.2.2 Drug Metabolism and Inhibition of CYP450 Enzymes, 355
 - 13.2.3 Protein Binding, 356
 - 13.2.4 En Route to a Lead Series: *In Vivo* PK Studies, 358
- 13.3 Compound Profiling in Lead Optimization, 359
 - 13.3.1 Extended CYP Inhibition Studies, 359
 - 13.3.2 Mechanism-Based CYP Inhibition, 359
 - 13.3.3 Inhibition of Transport Proteins, 360
 - 13.3.4 Biopharmaceutical Classification of a Clinical Candidate (Classification of Potential Drugs into Biopharmaceutical Classification System or Biopharmaceutical Drug Disposition and Classification System), 360
- 13.4 Integration of Medicinal Chemistry, Biology, Physicochemical, and ADME Profiling: Strategies Toward Cycle Time Reductions, 362
 - 13.4.1 Planning Phase, 363
 - 13.4.2 Sample Preparation and Distribution, 364
 - 13.4.3 Compound QC, 365
 - 13.4.4 Determination of Physicochemical Properties, 367
 - 13.4.5 ADME Profiling: General Remarks, 369
 - 13.4.6 Metabolic Liability Profiling, 369
 - 13.4.7 Permeability Testing, 370
 - 13.4.8 CYP Inhibition Profiling, 372
- 13.5 Summary, 372
- References, 373

PART V	MEDICINAL CHEMISTRY BEYOND SMALL MOLECULES	379
14	The Role of Natural Products in Drug Discovery: Examples of Marketed Drugs	381
	<i>Lars Ole Haustedt and Karsten Siems</i>	
14.1	Natural Products and Natural Product Derivatives in Commercial Drugs,	381
14.2	Hit to Lead Optimization of Natural Product Hits,	397
14.3	Case Study 1: Taxol,	397
14.4	Case Study 2: Epothilone,	406
14.5	Case Study 3: Eribulin,	407
14.6	Case Study 4: Geldanamycin,	413
14.7	Case Study 5: Ingenol Mebutate (Picato),	417
14.8	Summary,	422
	References,	423
15	Peptidomimetics of α-Helical and β-Strand Protein Binding Epitopes	431
	<i>Nina Bionda and Rudi Fasan</i>	
15.1	Protein-Protein Interactions as Therapeutic Targets,	431
15.2	Peptidomimetics of α -Helical Protein Binding Epitopes,	433
15.2.1	α -Helix-Mediated PPIs,	433
15.2.2	Side-Chain Cross-Linked α -Helices,	435
15.2.3	Hydrogen-Bond Surrogate-Stabilized α -Helices,	442
15.2.4	Other Type I α -Helix Peptidomimetics,	443
15.2.5	Type III α -Helix Peptidomimetics,	445
15.3	Peptidomimetics of β -Strand Protein Binding Epitopes,	446
15.3.1	β -Strand-Mediated PPIs,	446
15.3.2	Type I β -Strand Peptidomimetics,	447
15.3.3	Type III β -Strand Peptidomimetics,	449
15.4	Conclusion,	452
	References,	453
16	<i>In Vivo</i> Imaging of Drug Action	465
	<i>Oliver Plettenburg and Matthias Löhn</i>	
16.1	Introduction,	465
16.2	Overview of Imaging Methods,	466
16.2.1	Fluorescence-Based Methods,	466
16.2.2	MRI,	470
16.2.3	CT,	470
16.2.4	PET/SPECT,	471
16.3	Imaging of Therapeutic Effects,	476
16.3.1	Cancer,	476
16.3.2	Diabetes,	483
16.3.3	CNS Disorders,	486
16.4	Conclusion and Outlook,	490
	References,	491